This HTML5 document contains 194 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n27http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00634/identifier/kegg-drug/
n30http://linked.opendata.cz/resource/AHFS/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00634/identifier/pubchem-substance/
foafhttp://xmlns.com/foaf/0.1/
n15http://linked.opendata.cz/resource/mesh/concept/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00634/identifier/drugbank/
n7http://linked.opendata.cz/resource/drugbank/company/
n4http://linked.opendata.cz/resource/drugbank/dosage/
n10http://linked.opendata.cz/resource/drugbank/mixture/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00634/identifier/national-drug-code-directory/
n29http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n21http://linked.opendata.cz/resource/drugbank/drug/DB00634/identifier/chemspider/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00634/identifier/chebi/
n25http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n26http://linked.opendata.cz/resource/drugbank/medicinal-product/
n14http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n23http://www.drugs.com/cdi/
n22http://linked.opendata.cz/resource/drugbank/property/
n31http://linked.opendata.cz/resource/drugbank/drug/DB00634/identifier/wikipedia/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00634/identifier/pharmgkb/
n9http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/resource/drugbank/drug/DB00634/identifier/pubchem-compound/
n6http://linked.opendata.cz/resource/atc/
n5http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00634
rdf:type
n3:Drug
n3:description
An anti-infective agent that is used topically to treat skin infections and orally for urinary tract infections. [PubChem]
n3:dosage
n4:271B5CDA-363D-11E5-9242-09173F13E4C5 n4:271B5CDB-363D-11E5-9242-09173F13E4C5 n4:271B5CDC-363D-11E5-9242-09173F13E4C5 n4:271B5CD6-363D-11E5-9242-09173F13E4C5 n4:271B5CD7-363D-11E5-9242-09173F13E4C5 n4:271B5CD8-363D-11E5-9242-09173F13E4C5 n4:271B5CD9-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Hull CA, Johnson SM: A double-blind comparative study of sodium sulfacetamide lotion 10% versus selenium sulfide lotion 2.5% in the treatment of pityriasis (tinea) versicolor. Cutis. 2004 Jun;73(6):425-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15224788 # Del Rosso JQ: Evaluating the role of topical therapies in the management of rosacea: focus on combination sodium sulfacetamide and sulfur formulations. Cutis. 2004 Jan;73(1 Suppl):29-33. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14959943 # Roth HW, Leimbeck R, Sonnenschein B, Anger CB, Weber S: [The effective antibacterial spectrum of sulfacetamide] Klin Monatsbl Augenheilkd. 1992 Mar;200(3):182-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1578876
n3:group
approved
n3:halfLife
7-12.8 hours
n3:indication
For the treatment of bacterial vaginitis, keratitis, acute conjunctivitis, and blepharitis.
n3:manufacturer
n7:271B5CB6-363D-11E5-9242-09173F13E4C5 n7:271B5CB7-363D-11E5-9242-09173F13E4C5 n7:271B5CB4-363D-11E5-9242-09173F13E4C5 n7:271B5CB5-363D-11E5-9242-09173F13E4C5 n7:271B5CB2-363D-11E5-9242-09173F13E4C5 n7:271B5CB3-363D-11E5-9242-09173F13E4C5 n7:271B5CBB-363D-11E5-9242-09173F13E4C5 n7:271B5CBC-363D-11E5-9242-09173F13E4C5 n7:271B5CB9-363D-11E5-9242-09173F13E4C5 n7:271B5CBA-363D-11E5-9242-09173F13E4C5 n7:271B5CB8-363D-11E5-9242-09173F13E4C5 n7:271B5CC1-363D-11E5-9242-09173F13E4C5 n7:271B5CBF-363D-11E5-9242-09173F13E4C5 n7:271B5CC0-363D-11E5-9242-09173F13E4C5 n7:271B5CBD-363D-11E5-9242-09173F13E4C5 n7:271B5CBE-363D-11E5-9242-09173F13E4C5 n7:271B5CB0-363D-11E5-9242-09173F13E4C5 n7:271B5CB1-363D-11E5-9242-09173F13E4C5
owl:sameAs
n25:DB00634 n29:DB00634
dcterms:title
Sulfacetamide
adms:identifier
n12:46504544 n13:PA451536 n16:5320 n17:D05947 n18:0998-0522-15 n19:DB00634 n20:63845 n21:5129 n31:Sulfacetamide
n3:mechanismOfAction
Sulfacetamide is a competitive inhibitor of bacterial para-aminobenzoic acid (PABA), an essential component for bacterial growth (according to the Woods-Fildes theory). The inhibited reaction is necessary in these organisms for the synthesis of folic acid.
n3:packager
n7:271B5CAF-363D-11E5-9242-09173F13E4C5 n7:271B5C97-363D-11E5-9242-09173F13E4C5 n7:271B5C98-363D-11E5-9242-09173F13E4C5 n7:271B5C95-363D-11E5-9242-09173F13E4C5 n7:271B5C96-363D-11E5-9242-09173F13E4C5 n7:271B5C9B-363D-11E5-9242-09173F13E4C5 n7:271B5C9C-363D-11E5-9242-09173F13E4C5 n7:271B5C99-363D-11E5-9242-09173F13E4C5 n7:271B5C9A-363D-11E5-9242-09173F13E4C5 n7:271B5C9F-363D-11E5-9242-09173F13E4C5 n7:271B5C84-363D-11E5-9242-09173F13E4C5 n7:271B5C9D-363D-11E5-9242-09173F13E4C5 n7:271B5CA6-363D-11E5-9242-09173F13E4C5 n7:271B5C9E-363D-11E5-9242-09173F13E4C5 n7:271B5C83-363D-11E5-9242-09173F13E4C5 n7:271B5CA9-363D-11E5-9242-09173F13E4C5 n7:271B5CAA-363D-11E5-9242-09173F13E4C5 n7:271B5CA7-363D-11E5-9242-09173F13E4C5 n7:271B5C87-363D-11E5-9242-09173F13E4C5 n7:271B5CA8-363D-11E5-9242-09173F13E4C5 n7:271B5C88-363D-11E5-9242-09173F13E4C5 n7:271B5CAD-363D-11E5-9242-09173F13E4C5 n7:271B5C85-363D-11E5-9242-09173F13E4C5 n7:271B5CAE-363D-11E5-9242-09173F13E4C5 n7:271B5C86-363D-11E5-9242-09173F13E4C5 n7:271B5CAB-363D-11E5-9242-09173F13E4C5 n7:271B5C8B-363D-11E5-9242-09173F13E4C5 n7:271B5CAC-363D-11E5-9242-09173F13E4C5 n7:271B5C8C-363D-11E5-9242-09173F13E4C5 n7:271B5C89-363D-11E5-9242-09173F13E4C5 n7:271B5C8A-363D-11E5-9242-09173F13E4C5 n7:271B5C8F-363D-11E5-9242-09173F13E4C5 n7:271B5C90-363D-11E5-9242-09173F13E4C5 n7:271B5C8D-363D-11E5-9242-09173F13E4C5 n7:271B5C8E-363D-11E5-9242-09173F13E4C5 n7:271B5C93-363D-11E5-9242-09173F13E4C5 n7:271B5C94-363D-11E5-9242-09173F13E4C5 n7:271B5C91-363D-11E5-9242-09173F13E4C5 n7:271B5C92-363D-11E5-9242-09173F13E4C5 n7:271B5C7D-363D-11E5-9242-09173F13E4C5 n7:271B5C7E-363D-11E5-9242-09173F13E4C5 n7:271B5C81-363D-11E5-9242-09173F13E4C5 n7:271B5C82-363D-11E5-9242-09173F13E4C5 n7:271B5C7F-363D-11E5-9242-09173F13E4C5 n7:271B5C80-363D-11E5-9242-09173F13E4C5 n7:271B5CA2-363D-11E5-9242-09173F13E4C5 n7:271B5CA3-363D-11E5-9242-09173F13E4C5 n7:271B5CA0-363D-11E5-9242-09173F13E4C5 n7:271B5CA1-363D-11E5-9242-09173F13E4C5 n7:271B5CA4-363D-11E5-9242-09173F13E4C5 n7:271B5CA5-363D-11E5-9242-09173F13E4C5
n3:synonym
N(1)-Acetylsulfanilamide Sulfacétamide N-(P-Aminobenzenesulfonyl)acetamide Sulfacetamida N-Acetylsulfanilamide P-Aminobenzenesulfonacetamide N-Sulfanilylacetamide Sulfanilazetamid Sulphacetamidum N-[(P-Aminophenyl)sulfonyl]acetamide Sulphacetamide Acetosulfamine Sulfacetamid N-Acetyl-4-aminobenzenesulfonamide N-((P-Aminophenyl)sulfonyl)acetamide N-Sulphanilylacetamide N(1)-Acetyl-4-aminophenylsulfonamide P-Aminobenzenesulfonoacetamide Sulfacetamidum N'-acetylsulfanilamide
n3:toxicity
Oral LD<sub>50</sub> Mouse : 16500 mg/kg. Side effects include moderate to severe erythema (redness) and moderate edema (raised kin), nausea, vomiting, headache, dizziness, and tiredness. Higher exposure causes unconsciousness.
n5:hasAHFSCode
n30:52-04-04
n3:mixture
n10:271B5C7B-363D-11E5-9242-09173F13E4C5 n10:271B5C7C-363D-11E5-9242-09173F13E4C5 n10:271B5C79-363D-11E5-9242-09173F13E4C5 n10:271B5C7A-363D-11E5-9242-09173F13E4C5 n10:271B5C77-363D-11E5-9242-09173F13E4C5 n10:271B5C78-363D-11E5-9242-09173F13E4C5 n10:271B5C75-363D-11E5-9242-09173F13E4C5 n10:271B5C76-363D-11E5-9242-09173F13E4C5 n10:271B5C73-363D-11E5-9242-09173F13E4C5 n10:271B5C74-363D-11E5-9242-09173F13E4C5 n10:271B5C71-363D-11E5-9242-09173F13E4C5 n10:271B5C72-363D-11E5-9242-09173F13E4C5 n10:271B5C6F-363D-11E5-9242-09173F13E4C5 n10:271B5C70-363D-11E5-9242-09173F13E4C5 n10:271B5C6D-363D-11E5-9242-09173F13E4C5 n10:271B5C6E-363D-11E5-9242-09173F13E4C5 n10:271B5C6C-363D-11E5-9242-09173F13E4C5
n3:salt
n14:hasConcept
n15:M0020737
foaf:page
n9:ava1674.shtml n23:sulfacetamide-drops.html n27:plexion.htm
n3:IUPAC-Name
n22:271B5CE1-363D-11E5-9242-09173F13E4C5
n3:InChI
n22:271B5CE7-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n22:271B5CE6-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n22:271B5CE3-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n22:271B5CE4-363D-11E5-9242-09173F13E4C5
n3:SMILES
n22:271B5CE5-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n22:271B5CDF-363D-11E5-9242-09173F13E4C5 n22:271B5CF7-363D-11E5-9242-09173F13E4C5
n3:logP
n22:271B5CF9-363D-11E5-9242-09173F13E4C5 n22:271B5CDD-363D-11E5-9242-09173F13E4C5 n22:271B5CE0-363D-11E5-9242-09173F13E4C5
n3:logS
n22:271B5CFA-363D-11E5-9242-09173F13E4C5 n22:271B5CDE-363D-11E5-9242-09173F13E4C5
n5:hasATCCode
n6:S01AB04 n6:D10AF06
n3:H-Bond-Acceptor-Count
n22:271B5CED-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n22:271B5CEE-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n22:271B5CE8-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n22:271B5CE9-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n22:271B5CEB-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n22:271B5CEA-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n22:271B5CEC-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Enteric bacteria and other eubacteria
n3:casRegistryNumber
144-80-9
n3:category
n3:containedIn
n26:271B5CCA-363D-11E5-9242-09173F13E4C5 n26:271B5CCB-363D-11E5-9242-09173F13E4C5 n26:271B5CC8-363D-11E5-9242-09173F13E4C5 n26:271B5CC9-363D-11E5-9242-09173F13E4C5 n26:271B5CCE-363D-11E5-9242-09173F13E4C5 n26:271B5CCF-363D-11E5-9242-09173F13E4C5 n26:271B5CCC-363D-11E5-9242-09173F13E4C5 n26:271B5CCD-363D-11E5-9242-09173F13E4C5 n26:271B5CD2-363D-11E5-9242-09173F13E4C5 n26:271B5CD3-363D-11E5-9242-09173F13E4C5 n26:271B5CD0-363D-11E5-9242-09173F13E4C5 n26:271B5CD1-363D-11E5-9242-09173F13E4C5 n26:271B5CD4-363D-11E5-9242-09173F13E4C5 n26:271B5CD5-363D-11E5-9242-09173F13E4C5 n26:271B5CC2-363D-11E5-9242-09173F13E4C5 n26:271B5CC3-363D-11E5-9242-09173F13E4C5 n26:271B5CC6-363D-11E5-9242-09173F13E4C5 n26:271B5CC7-363D-11E5-9242-09173F13E4C5 n26:271B5CC4-363D-11E5-9242-09173F13E4C5 n26:271B5CC5-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n22:271B5CF3-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n22:271B5CF5-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n22:271B5CF6-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n22:271B5CF8-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n22:271B5CF2-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n22:271B5CF1-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n22:271B5CF4-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n22:271B5CE2-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n22:271B5CEF-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n22:271B5CF0-363D-11E5-9242-09173F13E4C5